Ensayo clínico CyberKnife para próstata

Compartir:

La braquiterapia de alta tasa de dosis para próstata (Braquiterapia HDR) en comparación con CyberKnife para próstata: Comparación práctica
Donald B. Fuller, M.D., Abril 17, 2008

Resumen del Protocolo

Comparación Braquiterapia HDR CyberKnife
 
   DOSE DELIVERY

   Radiobiological Power (Hypofractionation)

   May deliver identical radiation fractionation

   Dose molding matches cancer distribution

   Spares urethra from high dose\

   Able to curve dose around rectum

   Can modulate dose to spare nerves

   Typical Accuracy

+/- 1 mm* +/- 1 mm**
 
SPECIFIC PROCEDURAL ASPECTS

   Hospitalization

No

   Invasive

No

   Operating Room

No

   Pain Management

No

   Follow-up protocol after completion

Comparable Comparable

   Pubic bones block HDR catheter placement

Occasional Not a factor
 
   SIDE EFFECTS

   Organs affected

Primarily urological Primarily urological

   Typical magnitude

Mild to moderate Mild to moderate

   Erectile Preservation

Favorable Favorable

   Complications

Rare Rare
 
OUTCOME ASSESSMENT

   PSA Response Year One

Appears identical Appears identical

   PSA Response Intermediate-term (2-3 yr)

Appears identical Appears identical

   PSA Response Long-term (>= 5 years)

Durable Not defined yet


*   Potential source of error > 1 mm – HDR delivery catheter migration; próstata swelling
**   Potential source of error > 1 mm – Prostate rotation and deformation

Summary: The radiation dose molding and delivery accuracy properties of HDR brachytherapy and CyberKnife radiosurgery are extremely similar. CyberKnife is more patient friendly in the short run. HDR brachytherapy has long-term documentation of durable efficacy, which CyberKnife presently lacks, due to the newness of the technology. Because of the capability of CyberKnife to effectively “clone” HDR brachytherapy radiation dose distribution and fractionation, there is an expectation that it will produce an identical long-term efficacy result compared with HDR brachytherapy, when used in comparably selected patients, pending confirmation by clinical trials.

Escrito por Donald B. Fuller, M.D. – Radioncólogo

Estados Unidos

SAN DIEGO: (858) 505-4100
GRATUITO: (800) 790-3526

México

GRATUITO: 01-800-681-1839

2010 © Todos los derechos reservados | www.sdcyberknife.com